Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Mar. 31, 2022
Current assets:
Cash and cash equivalents	$ 325,535	$ 406,704
Accounts receivable, net	29,648	23,296
Marketable securities	31,216	27,483
Inventories	21,222	7,584
Prepaid expenses and other current assets	18,750	22,498
Amount due from related party	458	580
Total current assets	426,829	488,145
Property and equipment, net	2,681	2,944
Operating lease right-of-use asset	7,501	7,961
Marketable securities, non-current	1,938	0
Other assets	21,181	20,961
Total assets	460,130	520,011
Current liabilities:
Accounts payable	9,552	12,250
Accrued expenses and other current liabilities	65,688	68,594
Deferred revenue	100,564	100,564
Amounts due to Pfizer	39,244	32,563
Cost share advance from Pfizer	8,555	33,818
Operating lease liability	2,256	2,148
Amounts due to related parties	382	393
Total current liabilities	226,241	250,330
Deferred revenue, non-current	350,565	375,706
Long-term operating lease liability	6,431	7,041
Long-term debt, less current maturities (related party)	358,700	358,700
Other liabilities	1,717	1,711
Total liabilities	943,654	993,488
Commitments and contingencies (Note 9)
Shareholders’ deficit:
Common shares, par value $0.000017727 per share, 564,111,242 shares authorized; 95,657,032 and 94,858,446 issued and outstanding at June 30, 2022 and March 31, 2022, respectively	2	2
Additional paid-in capital	807,127	795,935
Accumulated other comprehensive loss	(17,285)	(17,285)
Accumulated deficit	(1,273,368)	(1,252,129)
Total shareholders’ deficit	(483,524)	(473,477)
Total liabilities and shareholders’ deficit	$ 460,130	$ 520,011